RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus

Core Insights - Rocket Pharmaceuticals reported a narrower loss of 38 cents per share in Q4 2025, compared to a loss of 62 cents per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 42 cents [1][7] - The company did not generate any revenues in Q4 2025 and for the entire year of 2025 [1][8] Financial Performance - General and administrative expenses decreased by approximately 42% year over year to $14.7 million [5] - Research and development expenses were $29.3 million, down 21.6% from the previous year, reflecting more disciplined spending following organizational restructuring [5] - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $188.9 million, down from $222.8 million as of September 30, 2025, with expectations to fund operations into Q2 2027 [6] Pipeline Developments - The FDA accepted the resubmitted biologics license application (BLA) for Kresladi, with a decision expected on March 28, 2026 [9][10] - The pivotal phase II study for RP-A501, a gene therapy for Danon disease, is set to resume in H1 2026 after the FDA lifted the clinical hold [11][12] - The company is also developing RP-A601 for arrhythmogenic cardiomyopathy and plans to initiate clinical studies for RP-A701 for dilated cardiomyopathy by mid-2026 [13] Stock Performance - Rocket Pharmaceuticals' shares rose by 6.4% in after-hours trading following the earnings announcement [2] - The stock has increased by 36.7% over the past six months, outperforming the industry average rise of 22.4% [4]